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OBJECTIVEdUnlike visceral adipose tissue (VAT), the association between subcutaneous
adipose tissue (SAT) and obesity-related morbidity is controversial. In patients with type 2 dia-
betes, we assessed whether this variability can be explained by a putative favorable, distinct
association between abdominal superﬁcial SAT (SSAT) (absolute amount or its proportion)
and cardiometabolic parameters.
RESEARCHDESIGNANDMETHODSdWeperformedabdominalmagneticresonance
imaging (MRI) in 73 patients with diabetes (mean age 58 years, 83% were men) and cross-
sectionally analyzed fat distribution at S1-L5, L5-L4, and L3-L2 levels. Patients completed food
frequency questionnaires, and subgroups had 24-h ambulatory blood pressure monitoring and
24-h ambulatory electrocardiography.
RESULTSdWomen had higher %SSAT (37 vs. 23% in men; P , 0.001) despite a similar
meanwaistcircumference.Fastingplasmaglucose(P=0.046)and HbA1c(P=0.006)wereboth
lower with increased tertile of absolute SSAT. In regression models adjusted for age, waist
circumference, and classes of medical treatments used in this patient population, increased
%SSAT was signiﬁcantly associated with decreased HbA1c (b = 20.317; P = 0.013), decreased
daytime ambulatory blood pressure (b = 20.426; P = 0.008), and increased HDL cholesterol
(b =0 . 2 5 7 ;P = 0.042). In contrast, increased percent of deep SAT (DSAT) was associated with
increasedHbA1c (b=0.266;P = 0.040) and poorer heart rate variability parameters (P =0.030).
Although total fat and energy intake were not correlated with fat tissue distribution, increased
intakeoftransfattendedtobeassociatedwithtotalSAT(r=0.228;P=0.05)andDSAT(r=0.20;
P = 0.093), but not with SSAT.
CONCLUSIONSdAbdominal SAT is composed of two subdepots that associate differ-
ently with cardiometabolic parameters. Higher absolute and relative distribution of fat in
abdominal SSAT may signify beneﬁcial cardiometabolic effects in patients with type 2
diabetes.
Diabetes Care 35:640–647, 2012
I
ntra-abdominal visceral adipose tissue
(VAT), which is linked to cardiometa-
bolic risk (1–3), differs anatomically
and functionally from subcutaneous adi-
pose tissue (SAT) (4). In addition, abdom-
inal SAT is further separable into two
distinct subcompartments by the fascia
superﬁcialis: the superﬁcial SAT (SSAT)
and the deep SAT (DSAT) (5). Whereas
the abdominal SSAT subdepot is orga-
nized into tightly packed lobules, the
lobules in the DSAT subdepot are larger,
more irregular, and less well organized,
and may represent an intermediate tis-
sue organization between SSAT and
VAT (4).
An increasedproportionofVAT(6)is
frequently reported to be associated with
type 2 diabetes and lower heart rate vari-
ability, anindicatorforautonomicneurop-
athy,andthereforeincreasedcardiovascular
risk (7). In contrast with VAT (1–3), there
is less consensus regarding the association
between abdominal (8) and peripheral
SAT with disease risk, and both negative
andpositiveassociationshavebeenreported
(9–11). Recent studies suggest that abdo-
minalDSATmaybeassociatedwithdisease
parameters, much like VAT, particularly
insulin resistance (5,12,13). Yet, the as-
sociation between peripheral and abdo-
minal SAT and cardiometabolic risk is
weak, if not “paradoxical” (9,14), and it
isstillunknownwhether absolute or rel-
ative amount of abdominal SSAT is re-
sponsible for the putative “protective
effects” of abdominal SAT reported in
some of these studies.
RESEARCH DESIGN AND
METHODS
Study population
As part of baseline measurements in the
2-year Cardiovascular,Diabetes, andEth-
anol (CASCADE) randomized controlled
trial, a cross-sectional analysis was per-
formed in a subgroup of 73 men and
women, aged 41–73 years, with type 2 di-
abetes (deﬁned as fasting plasma glucose
[FPG] .126, HbA1c .6.5, physician diag-
nosis, or evidence of purchase of oral hy-
poglycemic medications) who underwent
magnetic resonance imaging (MRI) of the
abdomen. Persons were excluded if they
weresmokers,pregnant,lactating,orusing
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From
1The S. Daniel Abraham International Center for Health and Nutrition, and Department of Epidemi-
ology,FacultyofHealthSciences,Ben-GurionUniversityoftheNegev,Beer-Sheva,Israel;the
2Department
of Radiology, Soroka University Medical Center, Beer-Sheva, Israel; the
3Department of Clinical Bio-
chemistry and The S. Daniel Abraham Center for Health and Nutrition, Ben-Gurion University of the
Negev, Beer-Sheva, Israel; the
4Departmentsof Physiologyand Neuroradiology,Soroka UniversityMedical
CenterandZlotowskiCenterforNeuroscience,Ben-GurionUniversityoftheNegev,Beer-Sheva,Israel;the
5Departments of Internal Medicineand Diabetes, Soroka University Medical Center, Beer-Sheva, Israel; the
6Department of Cardiology, Soroka University Medical Center, Beer-Sheva, Israel; the
7Nuclear Research
Center Negev, Dimona, Israel; and the
8Channing Laboratory, Department of Medicine, Brigham and
Women’sHospitalandHarvardMedicalSchool,andDepartmentsofEpidemiologyandNutrition,Harvard
School of Public Health, Boston, Massachusetts.
Corresponding author: Iris Shai, irish@bgu.ac.il.
Received 22 August 2011 and accepted 4 December 2011.
DOI: 10.2337/dc11-1583. Clinical trial reg. no. NCT00784433, clinicaltrials.gov.
R.G. and I.S. contributed equally to this study.
© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited,theuseiseducationalandnotforproﬁt,andtheworkisnotaltered.Seehttp://creativecommons.org/
licenses/by-nc-nd/3.0/ for details.
640 DIABETES CARE, VOLUME 35, MARCH 2012 care.diabetesjournals.org
Cardiovascular and Metabolic Risk
ORIGINAL ARTICLEan insulin pump or injecting insulin more
than twice per day; had evidence of severe
diabetes complications (e.g., proliferative
retinopathy or advanced renal disease);
had autonomic neuropathy manifested as
postural hypertension or hypoglycemia
unawareness; had a fasting serum triglyc-
eride level .400 mg/dL or a serum creat-
inine level of $2m g / d L( 1 7 7mmol/L);
had liver dysfunction (greater than twice
the upper limit of normal of alanine ami-
notransferase and aspartate aminotransfer-
ase levels); had active cancer or received
chemotherapy in the last 3 years; or were
participating in another trial. The study
protocol was approved by the Soroka Uni-
versity Medical Center Medical Ethics
Board and Helsinki Committee. All partic-
ipants provided written informed consent.
MRI acquisition and image analysis
MRIscansoftheabdomenwereperformed
using a 1.5 Tesla machine (Intera, Philips
Medical Systems, Best, the Netherlands)
using a body coil. Subjects were examined
inthesupinepositionwitharmspositioned
parallel along the lateral sides of the body.
MRI scans demonstrating fat in the differ-
ent compartments were assessed using a
MATLAB-basedin-houseprogram(Fig.1).
Fat tissues of speciﬁca n a t o m i c a ll a n d -
marks were quantiﬁed. The MRI scan al-
lows visualizing the fascia superﬁcialis
as a ﬁne black line. To divide SSAT from
DSAT, we drew a continuous line over the
fascia superﬁcialis. After quantiﬁcation, fat
tissues were divided into color-coded
groups: superﬁcial subcutaneous fat =
dark blue; deep subcutaneous fat = light
blue; VAT = green; perimuscular fat (fat
surrounding and within the latissimus
dorsi and diaphragm) = purple; and non-
classiﬁed fat (fat surrounding the vertebrae
and fat depots unrelated to any of the
groups listed above) = red. Selecting the
speciﬁed fat mass area was performed
using a semiautomatic method (i.e., con-
nected pixels) or various manual tools,
such as rectangle/circle/polygon or free
hand for ﬁne adjustments and corrections
if needed. Quantiﬁcation of the fat mass
regions included the area of each fat type
andtheproportion(percentage)ofthetotal
area of all fat types. To obtain absolute
measurements in metric units, a scaling
procedurewasappliedbeforethesegmen-
tation to determine real pixel dimensions.
Finally, in accordance with other studies
(15), we calculated the fat distribution us-
ing the mean of the three slices: S1L5,
L5L4,andL3L2.Perimuscularandthenon-
classiﬁed fat tissues, totaling a negligible
fractionoftotalabdominalfat,wereomitted
from our analysis. All multivariate analyses
were performed twice, using the absolute
abdominal fat tissue distribution (SSAT,
DSAT, VAT) or the relative (in percent) of
each depot from total abdominal adipose
tissue (TAAT) (SSAT%, DSAT%, VAT%).
Clinical parameters
Anthropometricmeasures wereevaluated
as clinical estimates of whole-body adi-
pose tissue compartments. Participants
were weighed without shoes to the nearest
0.1 kg. Height was measured using a wall-
mounted stadiometer to the nearest mil-
limeter for determination of BMI. Waist
circumference was measured halfway be-
tween the last rib and the iliac crest by the
qualiﬁed study nurse, with the same type
of measuring tape. Mean blood pressure
from two measures was recorded after
resting, with the use of an automated sys-
tem (Datascop Acutorr 4, SOMA Technol-
ogy, Inc., Bloomﬁeld, CT). Blood samples
were drawn after at least an 8-h fast, and
currentuseofallmedicationwasrecorded.
To assess blood pressure and heart rate
variability,24-hambulatorybloodpres-
sure monitoring (OSCAR 2 oscillometric
SunTech Medical Model 222, Morrisville,
NC) and 24-h ambulatory electrocardi-
ography (ECG) (LIFECARD-CF, Delmar
Reynolds Medical Ltd., Hertfordshire, UK)
w e r ep e r f o r m e di nas u b s t u d yg r o u po fo u r
population (n =3 1a n dn = 37, respec-
tively).Heartratevariabilityparametersin-
cluded time domain variables (16): the
meandurationofthetimeintervalbetween
two R waves (RR), graphically presented in
the form of an RR interval tachogram; the
SD of all normal RR (SDNN); the mean of
allthe5-minSDsofNN(normalRR)inter-
vals during the 24-h period; the root mean
square successive difference, calculates
the square root of the mean of the squared
differences between successive NN inter-
vals over 24 h; and the 24-h triangular in-
dex, the integral of the density distribution
(i.e., the number of all NN intervals) di-
vided by the maximum of the density dis-
tribution, which is more inﬂuenced by the
lower than the higher frequencies. From
the24-hbloodpressuremonitor,wecalcu-
lated the average systolic and diastolic
blood pressure during the day (average of
records between 6 A.M. and 10 P.M.) and
night (average of records between 10 P.M.
and 6 A.M.). All medications in current use
were recorded and classiﬁed.
Dietary assessment
We evaluated dietary assessment by a
validated food-frequency questionnaire
(17) that included 127 food items and 3
portion-sizepicturesfor17items.Electronic
questionnaires ensured completeness of the
data by prompting the participant when a
question was not answered.
Statistical analysis
We divided our study population across
tertiles of SSAT (range 5,052–26,836
mm
2) and used both absolute and pro-
portional fat distribution for the analysis
Figure 1dMRI imaging of abdominal fat tissues compartments. The subcutaneous fascial plane
was delineated using the computer interface semiautomatic method, where initially an intensity-
based automatic segmentation was generated and presented followed by semimanual ﬁne tuning.
The area of each compartment was quantitated separately. Fat tissues of speciﬁc anatomical
landmarks were quantiﬁed and divided into color-coded groups as follows: dark blue, superﬁcial
subcutaneous fat; light blue, deep subcutaneous fat; green, visceral adipose tissue; and red, non-
classiﬁedfatdfatsurroundingthevertebraeandfatdepotsthatwereunrelatedtoeachofthegroups
listed above. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Superﬁcial subcutaneous fat depotto account for both subdepot adiposity
and interdepot distribution, respectively.
Fat distribution was calculated by divid-
ingeachfatdepotbyTAAT,creatingthree
newvariables:SSAT%,DSAT%,andVAT%.
ANOVA linear test was used to evaluate
the characteristics of the study popula-
tion across SSAT tertiles. We performed
multivariatelinearregressionmodels,ad-
justedforageandwaistcircumference,to
evaluate associations amongSSAT,anthro-
pometric measures, diet, blood biomark-
ers, 24-h ambulatory blood pressure
monitoring,and24-hambulatoryECGre-
cordings. Models including cardiovascu-
lar outcomes (24-h ambulatory blood
pressuremonitoringand24-hambulatory
ECG recordings) were further adjusted,
one at a time, for FPG or HbA1c.W ef u r -
ther performed similar models adjusted
one at a time to the various classes of
medical treatments used in this patient
population (insulin, oral hypoglycemic
medications, antihypertensive medica-
tions, and lipid-lowering medications)
and performedthesame models, stratiﬁed
by sex. The Statistical Package for the Social
Sciences(version19,SPSSInc.,Chicago,IL)
wasusedforall statisticalanalyses.P,0.05
denotedstatisticalsigniﬁcance.P valuewas
notadjustedformultipletesting.Valuesre-
ported are means 6 SDs unless otherwise
stated.Multiplelinearregressionresultsare
reportedwiththeparameterestimateand
P value for each variable.
RESULTS
Fat distribution, blood biomarkers,
and diet
The baseline characteristics of the partici-
pants in the entire study group and acros-
stertilesofSSATareshowninTable1.Mean
HbA1c was 7.5 6 1.1%, and 10 (14%) pa-
tients were taking one daily dose of insulin.
The oralhypoglycemicmedications usedby
the patients included sulfonylureas (11
patients,15%), dipeptidyl peptidase-4 in-
hibitor (9 patients, 12%), and metformin
(31 patients, 42%). None of the patients
were taking thiazolidinediones. The mean
fattissuesdistributionwasasfollows:SSAT
26%, DSAT 23%, and VAT 51%. SSAT
positively correlated with DSAT (r =
0.389, P , 0.001) and TAAT (r =0 . 4 6 1 ,
P , 0.001). SSAT, DSAT, and TAAT cor-
related positively and signiﬁcantly with
waist circumference (SSAT: r =0 . 3 1 3 ,P =
0.009, DSAT: r =0 . 2 7 6 ,P = 0.023, TAAT:
r =0 . 4 4 9 ,P , 0.001) and BMI (SSAT: r =
0.490, P , 0.001, DSAT: r =0 . 3 2 7 ,P =
0.005, TAAT r =0 . 5 0 8 ,P , 0.001). VAT
correlated positively and signiﬁcantly with
waist circumference and weight (r = 0.330,
P=0.006;r=0.346,P=0.003,respectively).
Medicaltreatment,includinginsulintherapy
and antihypertensive, lipid-lowering, anti-
platelet,andoralhypoglycemicmedications,
wassimilarlydistributedacrossSSATtertiles
(Table 1).
FPG (P of trend = 0.046, P = 0.073
between extreme tertiles) and HbA1c(P of
trend=0.006,P=0.011betweenextreme
tertiles) were both lower with increased
tertile of SSAT. SSAT was inversely corre-
latedwithHbA1C(r=20.262,P=0.027),
whereas VAT (r = 0.240, P = 0.042) and
TAAT positively correlated with fasting
triglycerides (r = 0.278, P = 0.018).
In a regression model (Fig. 2A), ad-
justed for age and waist circumference,
increased absolute SSAT was associated
with decreased HbA1c (b = 20.289, P =
0.017) and tended to be associated with
decreased fasting glucose (b = 20.208,
0.084). Further adjustment of the model
to medical treatment classes (one at a
time: insulin therapy and antihyperten-
sive, lipid-lowering, antiplatelet, and
oral hypoglycemic medications) did not
signiﬁcantly attenuate these associations
(data notshown).Totalenergy intake, to-
tal dietary fat, saturated fat, and unsatu-
rated fat content were not associated with
fat tissue mass (data not shown). How-
ever,increasedtotaldietaryintakeoftrans
fatty acids tended to be positively corre-
latedwithtotalSAT(r=0.228,P =0.054)
and DSAT (r =0 . 2 0 0 ,P = 0.093). Collec-
tively, the absolute area (mass) of abdom-
inal SSAT seemed to be associated with
more favorable glycemic and cardiovas-
cular parameters, unlike DSAT or VAT.
Proportional fat tissue distribution
We next assessed whether the relative adi-
pose tissue distribution, i.e., the percentage
of fat in a certain abdominal (sub)-depot,
was associated with clinical parameters.
The percentage of SSAT from TAAT
(%SSAT) was associated with lower
HbA1c in regression models adjusted for
age and waistcircumference (b= 20.304,
P = 0.017), consistent with the ﬁnding
using the absolute SSAT area mentioned
above. When we added medical treat-
ment to the model (insulin therapy and
antihypertensive,lipid-lowering,antipla-
telet,andoralhypoglycemicmedications),
the association remained signiﬁcant. Con-
versely, increased DSAT was associated
with increased levels of HbA1c (b =
0.266, P = 0.039) and fasting glucose
(b = 0.246, P = 0.054). Increased %SSAT
was associated with increased HDL cho-
lesterol (b = 0.251, P = 0.047) (Fig. 3A).
Of the 12 women recruited, 11 were
postmenopausal, none of whom were
taking hormone replacement therapy.
Although men and women had similar
waistcircumferences(104vs.103cm,P=
0.902), TAAT (37,095 vs. 37,108 mm
2,
P = 0.975), and medical treatment,
women had higher %SSAT than did
men and twice the ratio of SSAT to VAT
(Table 2). They had lower fasting glucose
(P,0.001)andlowerHbA1c(P=0.002),
and tended to have higher HDL choles-
terol (P = 0.076). Men had a higher VAT
to SAT ratio, whereas %DSAT was similar
between men and women. To verify that
the association between SSAT and favor-
able cardiometabolic parameters did not
simply reﬂect intrinsic differences between
genders,westratiﬁedtheregressionmodels
Figure 2dAssociation of metabolic parame-
ters and cardiovascular parameters with ab-
solute abdominal fat tissues in patients with
type 2 diabetes, stratiﬁed by sex. A: Entire
group. B: Men only. Multivariate model ad-
justed for age and waist circumference. SSAT
(black bar). DSAT (white bar). Numbers rep-
resent b standardized coefﬁcient: the amount
and direction by which absolute abdominal fat
tissueschange(mm
2)foreachunitchangeinthe
metabolic parameters, while accounting for the
other variables in the model. TG, triglycerides
(mg/day). *P , 0.05. †P , 0.1.
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Golan and Associatesby sex (Figs. 2B and 3B). In a subgroup of
the men only,similar opposite associations
among %SSAT, %DSAT, and cardiometa-
bolic parameters were observed (Fig. 3B).
In addition, in the men-only subgroup, %
DSAT was signiﬁcantly associated with
higher glucose (b =0 . 2 9 2 ,P =0 . 0 4 0 )a n d
HbA1c (b =0 . 2 9 8 ,P =0 . 0 3 8 ).
Fat distribution, 24-h ambulatory
blood pressure monitoring, and
24-h ambulatory ECG
We further found associations among the
absolute abdominal subdepot fat (mass),
proportional abdominal subdepot fat area,
blood pressure, and heart rate variability
parameters: Both absolute (r = 20.381,
P = 0.050) and proportional DSAT (r =
20.428, P = 0.026) negatively correlated
with SDNN. In regression models, ad-
justed for age and waist circumference,
higher absolute DSAT (b = 20.425, P =
0.034)andhigherproportionalDSAT(b=
20.431 P = 0.029) were associated with
lower SDNN. Proportional DSAT was sig-
niﬁcantly associated with decreased 24-h
triangular index (b = 20.417, P = 0.030),
suggesting decreased heart rate variability
with increased fat distribution to the
DSAT depot. However, further adjust-
ment to oral hypoglycemic medications,
but not to insulin therapy, antihyperten-
sive, lipid-lowering, or antiplatelet drugs,
attenuated the association between DSAT
and markers of heart rate variability (24-h
triangular index: b = 20.249, P = 0.228,
SDNN: b = 20.294, P = 0.186). Because
hyperglycemia is a key risk factor for au-
tonomic neuropathy, we further adjusted
the models, one at a time, for HbA1c or
FPG. The association between both abso-
luteandproportionalDSATandheartrate
variability remained negative, but the sig-
niﬁcance was attenuated. When adjusted
for HbA1c, higher absolute (b = 20.355,
P = 0.093) and proportional (b = 20.401
P = 0.073) DSAT were associated with
lowerSDNN.ProportionalDSATwasneg-
atively associated with decreased 24-h
triangular index (b = 20.406, P =0 . 0 6 3 ) .
Whenadjustedforglucose,higherabsolute
(b = 20.278 P = 0.144) and proportional
(b = 20.322 P = 0.122) DSAT were not
associated with lower SDNN. In contrast,
opposite trends were observed with absolute
and proportional abdominal SSAT: Higher
absolute(b=20.329,P=0.043)andpro-
portional SSAT (b = 20.425, P = 0.008)
were associated with lower mean daytime
diastolic blood pressure. When medical
treatmentwasaddedtothemodel(insulin
therapy, antihypertensive, lipid-lowering,
antiplatelet,ororalhypoglycemicmedica-
tions), the association remained signiﬁ-
cant. Increased proportional SSAT tended
to positively correlate with increased
Table 2dAbdominal fat tissue distribution, biomarkers, and clinical parameters
in men and women with type 2 diabetes
Men Women
Age, years 58.4 6 7.5 59.7 6 7.2
Weight, kg 87.7 6 13.1 81.5 6 13.4
BMI, kg/m
2 28.9 6 3.7 31.2 6 3.8
Systolic blood pressure, mmHg 134.9 6 14.5 144.0 6 25.0
Diastolic blood pressure, mmHg 78.7 6 10.4 80.7 6 8.7
Waist circumference, cm 104.0 6 9.2 103.5 6 9.5
Abdominal MRI
Total SAT, mm
2 17,080 6 5,312 22,825 6 7,230*
Abdominal SSAT, mm
2 8,587 6 2,673 13,898 6 5,357†
Abdominal DSAT, mm
2 8,493 6 3,403 8,927 6 3,691
VAT, mm
2 20,014 6 6,629 14,355 6 3,838*
TAAT, mm
2 37,095 6 8,848 37,180 6 7,290
Fat distributions
Abdominal SSAT: total adipose tissue ratio 0.22 6 0.05 0.36 6 0.09†
Abdominal SSAT: total SAT ratio 0.51 6 0.1 0.60 6 0.1*
Abdominal SSAT: VAT ratio 0.47 6 0.2 1.05 6 0.5†
VAT: total abdominal SAT ratio 1.28 6 0.5 0.69 6 0.3†
Fasting blood biomarkers
Plasma glucose, mg/dL 144.6 6 40.3 118.2 6 11.8*
HbA1c, % 7.6 6 1.1 6.9 6 0.4*
Serum TG, mg/dL 162.2 6 83.2 154.0 6 54.0
Serum HDL cholesterol, mg/dL 44.1 6 10.1 50.0 6 8.2*
Serum LDL cholesterol, mg/dL 94.5 6 29.7 108.8 6 29.3
TG/HDL 3.8 6 2.3 3.4 6 1.9
Plasma alkaline phosphatase, units/L 73.8 6 28.7 60.4 6 14.8
Plasma alanine aminotransferase, units/L 27.3 6 11.3 23.5 6 7.7
Medications in current use
Lipid-lowering therapy, n (%) 36 (59) 8 (66)
Antihypertensive therapy, n (%) 32 (52) 9 (75)
Oral glycemic-control medications, n (%) 42 (69) 9 (75)
Oral antiplatelet drugs, n (%) 28 (46) 7 (58)
Data are means 6 SD unless otherwise indicated. n = 61 and 12 for men and women, respectively. TG,
triglycerides. *P , 0.05. †P , 0.001. To convert values for cholesterol to millimoles per liter, multiply by
0.02586.Toconvertvaluesfortriglyceridestomillimolesperliter,multiplyby0.01129.Toconvertvaluesfor
glucose to millimoles per liter, multiply by 0.05551.
Figure 3dAssociation of metabolic and car-
diovascular parameters with abdominal fat
t i s s u e sd i s t r i b u t i o ni np a t i e n t sw i t ht y p e2d i a -
betes, stratiﬁed by sex. A:E n t i r eg r o u p .B:M e n
only. Multivariate model, adjusted for age and
waistcircumference.SSAT%(blackbar).DSAT%
(whitebar).Numbersrepresentbstandardized
coefﬁcient: the amount and direction by which
proportional abdominal fat tissues change (%)
for each unit change in the metabolic param-
eters,while accountingfor the other variables in
themodel.TG,triglycerides(mg/day).*P,0.05.
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Superﬁcial subcutaneous fat depotsquare root of the mean of the squared
differences between successive NN inter-
vals over 24 h (r =0 . 3 6 7 ,P = 0.060).
When HbA1c was added to the model,
the association between absolute SSAT
and meandaytimediastolicblood pressure
was attenuated (b = 20.284, P = 0.072),
although the association between propor-
tional SSAT and mean daytime diastolic
blood pressure remained signiﬁcant (b =
20.379, P = 0.008). When adjusted for
glucose, the association between both ab-
solute (b = 20.329, P = 0.043) and pro-
portional (b = 20.444, P = 0.006) SSAT
and mean daytime diastolic blood pres-
sure remained signiﬁcant.
When the models were stratiﬁed by
sex, we found that the men-only sub-
group also exhibited similar associations
amongabdominalsubdepotfat(massand
proportion), blood pressure, and heart
rate variability parameters. Higher abso-
lute DSAT (b = 20.452, P = 0.014) and
proportional DSAT (b = 20.535 P =
0.009) were associated with lower SDNN.
Higher absolute DSAT (b = 20.486, P =
0.007) and proportional DSAT (b =
20.557, P = 0.005) were associated
with decreased 24-h triangular index.
Further adjustment to oral hypoglyce-
mic medications, but not to insulin ther-
apy, antihypertensive, lipid-lowering, or
antiplatelet drugs, attenuated the associ-
ation between proportional DSAT and
markers of heart rate variability (24-h tri-
angular index: b = 20.439, P =0 . 0 7 5 ,
SDNN: b = 20.443, P = 0.074) and be-
tween absolute markers of heart rate vari-
ability (24-h triangular index: b = 20.408,
P =0 . 0 7 3 ,S D N N :b = 20.408,P =0 . 0 7 2 ) .
CONCLUSIONSdIn this study of pa-
tients with type 2 diabetes, we observed a
distinct association between both the
absolute (representing “sub-depot adi-
posity”) and the relative amounts (repre-
senting interdepot distribution) of
abdominal SSAT and markers of more fa-
vorableglycemiccontrolandcardiovascu-
lar function as determined by higher heart
rate variability and lower blood pressure.
After adjusting for age and waist circum-
ference, higher relative distribution of ab-
dominal fat in SSAT was correlated with
improved glycemic control (HbA1c and
fasting glucose) and better indicators of
cardiovascular health (lower blood pres-
sure and higher heart rate variability).
Conversely, DSAT correlated with higher
heart rate and lower heart rate variabil-
ity,bothindicatorsofautonomicneurop-
athy (18), and therefore indicators for
increased cardiovascular risk. Of note,
controlling for markers of glycemic con-
trolattenuatedthenegativeassociationbe-
tween DSAT and cardiovascular end
point, but not the favorable association
with SSAT. In terms of diet, increased in-
take of trans fat tended to be associated
with total abdominal SAT and DSAT, but
not with SSAT. Because most studies sup-
port the more “adverse metabolic role” of
intraabdominal/VAT, whether SAT issim-
ply “less pathogenic” than VAT or exerts
direct or indirect “protective effects” on
cardiovascular and metabolic morbidity
is still controversial (6,9). Furthermore,
even more uncertainty exists as to the
functional differences and risk associated
with the DSAT or SSAT subdepots in per-
sonswithtype2diabetes(19).Ourresults
suggest a favorable distinct association be-
tween abdominal SSAT subdepot and car-
diometabolic health in type 2 diabetes.
Our study has several limitations.
This is a cross-sectional design that may
suggest associations but not clear cause–
effect protective relationships between
abdominal SSAT and cardiometabolic pa-
rameters. Becausewedidnotmeasurepe-
ripheral (lower body) SAT, our results
refer to abdominal SSAT only. Our sample
size limits the statistical power, although
we still could identify signiﬁcant differ-
ences between parameters. A signiﬁcant
proportion of our patients received treat-
ment with medications that may modify
the levels of risk factors and directly affect
glycemiccontrolparameters.Althoughwe
havemadeanattempttoadjustourresults
to the use of these drugs, doses were not
assessed. Finally, we had a lower propor-
tion of women, but nevertheless we could
identify signiﬁcant differences between the
sexes. The strengths of our study include
the speciﬁc group with type 2 diabetes, the
high MRI quality imaging, the compre-
hensive 24-h ambulatory blood pressure
and 24-h ambulatory ECG measurements
as cardiometabolic measurements, the
medication follow-up, and the dietary
assessment.
We found that abdominal SSAT cor-
related with improved glycemic control
and indicators of cardiovascular risk. The
SSAT depot may be less lipolytic than
VAT, or even DSAT, and so improved in-
sulin sensitivity of SSAT may favor accu-
mulation of excess energy in this depot. In
this regard, higher deposition of excess
calories in the SSAT is a consequence, not
the cause, of improved metabolic func-
tion. Conversely, it is plausible that the
abdominal SSAT fat mass may be a unique
abdominal fat subdepot that has protec-
tive effects on glycemic control and car-
diovascular function. This is reminiscent
of a ﬁnding by some, but not all, studies
that suggest peripheral SAT might be less
“pathogenic” than VAT. Currently, two
hypotheses have been put forward to ex-
plain the difference between peripheral
SAT and VAT: The “portal theory” (6,20)
implicates a direct mechanism whereby
VAT is more pathogenic because its ve-
nousblooddrainageisdirectlyviathepor-
t a lv e i nt ot h el i v e r .T h e“ectopic fat
hypothesis”(6)suggestsanindirectmech-
anism whereby increased energy storage
inperipheral SAT exerts aprotective effect
by decreasing fat deposition in the liver,
muscle, and heart. Because abdominal
DSAT exhibits an intermediate phenotype
between VAT andabdominalSSATinvar-
iousfunctionstested(lipolysis,adipocyto-
kine proﬁle) (4), it is possible that these
theories can underlie the unique positive
association between abdominal SSAT and
cardiovascular and metabolic health. Al-
though it may be possible that peripheral
SAT differs signiﬁcantly from abdominal
SAT, and some studies have indicated the
potential pathogenic role of increased
abdominal (total) SAT as opposed to pe-
ripheral SAT (9–11), further studies are
required to fully understand the distinct
role of the SSAT subdepot. It is tempting
to speculate that discrepancies in the liter-
atureamongstudiesassessingassociations
between abdominal SAT and morbidity
were conﬁned by differences in the SSAT
or SSAT/DSAT distribution.
Nutritional habits may also affect fat
distribution. In our study, increased trans
fatty acids consumption tended to be asso-
ciated with increased total abdominal SAT
andDSAT,butnotSSAT.Limitedevidence
has suggested that increased dietary intake
of trans fatty acids may increase fat accu-
mulation and abdominal circumference
(21,22). Although these studies emphasize
the increase in VAT, our ﬁndings suggest
that DSAT also may be increased by exces-
sive intake of trans fatty acids.
Women in our study had a higher
proportion of abdominal SSAT, whereas
men had a higher intra-abdominal fat to
subcutaneous fat ratio. The proportion of
DSAT was similar in men and women.
Similar ﬁndings have been shown by
other cohorts (12,23,24). Fat is distrib-
uted in a sexual dimorphic manner, be-
y o n dt h ed i f f e r e n c e sb e t w e e nu p p e rb o d y
(more in men) versus lower body loca-
tions (more in women). For a given
amount of intra-abdominal fat, women,
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metabolic morbidity, at least before men-
opause (6), possess up to twice as much
subcutaneous fat as men (25,26). Of note,
although sexual dimorphism in fat distri-
bution usually tends to diminish with
postmenopausal state, we observed such
changes in our cohort despite the fact that
most (11/12) women were postmeno-
pausal. This ﬁnding may complement a
prior report that postmenopausal women
who possess a higher proportion of adi-
pose tissue located in the total midthigh
depothadamorefavorablemetabolicpro-
ﬁle (25).Althoughstudieshavereported an
association between hormone replace-
ment therapy and cardiovascular health
(27,28), none of the women in our study
were on such therapy. Future studies will
unravel whether increased abdominal
SSAT and its seemingly favorable meta-
bolic and cardiovascular correlates dimin-
ish with years into menopause, or have
other determinants, possibly unique to
persons with diabetes.
Finally, it has been proposed that anti-
diabetic medications, particularly of the
thiazolidinedione family, may exert their
therapeutic effect at least partially by in-
ducing redistribution of fat from “patho-
genic” to “less-pathogenic” depots (e.g.,
from VAT to SAT) (29,30). However,
none of the patients in our study were re-
ceiving thiazolidinedione therapy. Other
hypoglycemic medications were distrib-
uted similarly among tertiles of SSAT and
controlled for in the regression models.
In summary, the current study adds
to the understanding of the pattern of
abdominal fat distribution, including
“sub-depots,” and its relation to glycemic
control and cardiovascular risk in diabetic
patients. Effective interventions that can
alter abdominal fat distribution may help
sort out whether fat distribution pheno-
typesaremerelyareﬂectionofobesitysub-
phenotypes or can causally affect risk and
severity of obesity-associated morbidities.
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